# Caffeine strategies for cognitive performance in healthy adults (20–65): dosing, timing, patterns, L‑theanine co‑ingestion, tolerance, sleep, and safety (2017–2025 evidence)

## Executive summary
- Acute caffeine reliably improves vigilance, reaction time (RT), and sustained attention in rested adults with small–moderate effects, and after sleep loss with moderate–large effects. Best day‑time doses are ~200–300 mg or ~3 mg/kg taken 30–60 min pre‑task; higher doses do not consistently add cognitive benefit and increase side effects [1–2,6–9,11,13].
- For prolonged wake/overnight work, split/maintenance dosing (e.g., 200 mg every 2–4 h, or 2 mg/kg repeated) targeted to the circadian trough preserves vigilance better than a single bolus, though performance does not fully normalize [3–5].
- Co‑ingesting L‑theanine with caffeine, at moderate (~160 mg caffeine + 200 mg theanine; ~1.25:1) to high (1:1 mg/kg) ratios, improves attentional speed/accuracy vs placebo and, in head‑to‑head sports trials, outperforms caffeine alone on Stroop RT and accuracy; EEG/fMRI data suggest better allocation of attentional resources and reduced mind‑wandering. Tea‑equivalent low doses show mixed effects and context‑dependent interactions [21–23,26,29–30].
- Sleep: 30 mg caffeine at bedtime increased WASO, which was prevented by 50 mg L‑theanine co‑ingestion; more generally, even 400 mg caffeine taken 6 h before bedtime disrupts sleep, supporting a ≥6–8 h “caffeine curfew” [5,38]. Official guidance: up to 400 mg/day and single 200 mg doses are generally safe for healthy adults; small evening doses can still affect sleep [35–36].
- Tolerance: A 10‑day, thrice‑daily 150 mg regimen impaired working‑memory performance and showed withdrawal effects on discontinuation, indicating adaptation; acute attentional benefits do not appear moderated by habitual use in meta‑analysis. There are no randomized tests of cycling/deload schedules; pragmatic caps and curfews are advisable to preserve efficacy [1,14].

## What outcomes improve with caffeine (alone)?
- Rested adults: Meta‑analysis of randomized trials (n=31; 1,455 participants) found small–moderate improvements in attention RT (g≈0.28) and accuracy (g≈0.27). Meta‑regression showed a positive linear dose–response for RT, and a quadratic (inverted‑U) for accuracy that peaks at low‑to‑moderate doses (≥200 mg), with accuracy declining at higher doses [1].
- After sleep loss: Meta‑analysis across sleep‑restricted/deprived protocols reported larger benefits—attention RT g≈0.86 and accuracy g≈0.68—with task‑dependent effects across 80–600 mg doses [2]. Randomized crossover trials during total sleep deprivation (TSD) show immediate, near two‑fold PVT improvements after nighttime 200–300 mg doses, with little added value of 300 vs 200 mg per dose [3]. Repeating 200 mg every ~2 h overnight sustained better PVT speed/fewer lapses over multiple nights, without full normalization [4]. Splitting 6 mg/kg into three 2 mg/kg doses across a TSD night improved RT and detections vs placebo [5].
- Dose–response in executive attention: In rested adults, 3 mg/kg consistently speeds Stroop RT without harming accuracy; 6 mg/kg sometimes helps speed but with more nervousness; 9 mg/kg does not add benefit [6–7,13]. Field‑relevant data show 3 mg/kg improves visuomotor speed and accuracy in esports and shooting tasks [8–10].
- Other cognitive domains: Fixed 200 mg improved shifting attention and reduced brake RT in driving simulation at ~30–60 min post‑dose [11]. Dynamic visual acuity accuracy and RT improved at 4 mg/kg [12].

## Dosing pattern: single bolus vs split/maintenance; immediate‑ vs sustained‑release; source/form
- Bolus in rested daytime work: 200–300 mg (2.5–4 mg/kg) 30–60 min pre‑task yields small–moderate RT/attention gains; accuracy benefits plateau beyond this range [1,6–8,11,13].
- Maintenance dosing for extended wake/overnight: 200 mg every 2–4 h or repeated 2 mg/kg doses outperform single bolus for vigilance across the night, with disproportionate benefit at the circadian trough [3–5].
- Formulations and absorption:
  - Gum: Rapid absorption similar to beverages (tmax comparable), but one PK study found gum delivered ~18% less caffeine than coffee at the same nominal dose; adjust dose to match delivered amount [15]. Gum is useful when dosing close to task start (≤15–30 min) [15,20].
  - Sustained‑release (SR): 200 mg SR had much later tmax (~4 h vs ~0.8 h for IR), similar exposure (AUC), and better late‑day alertness/lower jitteriness (8–12 h). Onset is slower; cognitive outcomes were not directly tested [16].
  - “Fast” sublingual sprays: 60 mg mouth spray did not produce faster systemic peaks vs coffee or energy drink, and no form‑related cognitive differences were observed [17].
  - Energy drinks vs matched caffeine: At 320 mg, energy drinks caused greater QTc prolongation and higher central systolic BP than caffeine‑only drinks, implicating non‑caffeine constituents; prefer pure caffeine sources if cardiovascular safety is a concern [18].
  
## Timing relative to wake time, task time, bedtime, and circadian phase
- Pre‑task timing: Capsules/liquids—peak performance benefits at ~30–60 min post‑ingestion; gum permits closer dosing (≤15–30 min) due to rapid absorption [6,8,11,15].
- Circadian phase: Under TSD, dosing targeted to the circadian trough (night/early morning) yields outsized vigilance benefits; repeated nighttime doses sustain performance better than a single bolus [3–5].
- Bedtime/sleep timing:
  - 30 mg caffeine at bedtime increased WASO; adding 50 mg theanine prevented this WASO increase (sleep latency and TST unchanged) [5].
  - A controlled trial with 400 mg caffeine taken 0, 3, or 6 h before bedtime significantly disrupted sleep even at 6 h (≈41 min loss of TST), supporting a ≥6–8 h caffeine curfew for most adults [38].
  - EFSA concluded single 100 mg doses can adversely affect sleep when consumed close to bedtime, and 200 mg in the evening/night can reduce sleep duration; EFSA also deems up to 200 mg per dose and up to 400 mg/day generally safe for healthy adults [35].

## Co‑ingestion with L‑theanine: dose ratios, timing, cognitive and sleep outcomes
- Meta‑analysis (RCTs): Theanine+caffeine vs placebo showed small improvements in attention switching accuracy (SMD 0.33 [0.13, 0.54]) and digit vigilance accuracy (SMD 0.20 [0.02, 0.38]) at 1–2 h post‑dose; choice RT improved at ~1 h but with wide confidence intervals (SMD −0.48 [−1.01, 0.05]). Doses typically 40–160 mg caffeine with 50–200 mg theanine; testing 30–120 min post‑dose [21].
- Moderate supplement doses (~160 mg caffeine + 200 mg theanine; ratio ~1.25:1), 50–60 min pre‑task:
  - Rested men: Faster target RT vs placebo and fMRI patterns consistent with reduced mind‑wandering; factorial analysis suggested synergy on sustained attention [22].
  - Sleep‑deprived adults (N=37): Combination improved target RT by an additional ~38 ms vs placebo, with higher hit rate and greater target‑distractor discriminability; P3b ERP amplitude increased and latency decreased, indicating enhanced/faster attentional resource allocation [23–24].
- High sport doses (1:1 mg/kg):
  - Elite curlers: 6 mg/kg caffeine + 6 mg/kg theanine outperformed caffeine‑only and theanine‑only on Stroop RT (neutral, congruent, incongruent) and error rates at ~60 min post‑dose [26].
- Low “tea‑equivalent” doses:
  - Bedtime sleep study: 30 mg caffeine increased WASO; adding 50 mg theanine suppressed the WASO increase [5].
  - Pre‑2017 attention studies (40–50 mg caffeine + ~100 mg theanine) improved task switching vs placebo, but at some low‑dose ratios theanine attenuated caffeine’s behavioral/mood effects and cerebral vasoconstriction signature—showing context‑dependent interactions [29–31].
- Theanine alone: Dose–response trials suggest 100–200 mg can speed simple RT in rested adults, and selective attention may improve after sleep deprivation; these profiles likely underlie additive effects with caffeine [27–28].
- Safety/jitteriness: At low/tea‑equivalent doses, theanine blunted caffeine‑related BP increases in earlier RCTs, but acute reductions in jitteriness are inconsistent in contemporary trials; high‑quality head‑to‑head anxiety/jitteriness data (combo vs caffeine alone) remain sparse post‑2017 [29–32].

## Dose expression (mg/kg vs fixed mg) and practical ranges
- For most adults (60–90 kg), 200–300 mg approximates 2.5–4 mg/kg; mg/kg dosing is preferable when body mass varies (e.g., athletes). Consistent cognitive RT improvements are seen at ~3 mg/kg; 6 mg/kg sometimes helps RT but increases nervousness; ≥9 mg/kg adds little or no cognitive benefit [6–7,13].
- Beverage equivalence and label awareness: FDA reports typical caffeine amounts vary widely by beverage and brand (e.g., ~80–100 mg per 8‑oz coffee; energy drinks often 70–300+ mg per serving); match total daily dose to guideline caps and consider formulation effects [36].

## Anxiety symptoms, cardiovascular signs, and sleep disruption
- Anxiety/nervousness: Increased “nervousness” and “activeness” after 6 mg/kg vs placebo; 3 mg/kg produced fewer side effects while improving RT [13]. SR 200 mg produced less late‑day jitteriness than 200 mg IR with similar exposure [16].
- Heart rate/BP/QTc: Pure caffeine at 200–300 mg in lab settings had minimal adverse events in healthy adults; large energy drink (320 mg caffeine) caused greater QTc prolongation and higher central BP than matched caffeine alone, implicating other drink constituents [18].
- Sleep disruption:
  - Rested adults: Even 6 h pre‑bedtime, 400 mg caffeine reduces sleep duration; EFSA notes 100 mg near bedtime can disturb sleep. Strict curfew and dose capping help minimize next‑day sleepiness [35,38].
  - Theanine co‑ingestion can mitigate small nighttime caffeine doses’ WASO effect (30 mg caffeine + 50 mg theanine at bedtime), but avoidance of evening caffeine remains the primary strategy [5].

## Tolerance development, deloads/cycling, and sustained efficacy ≥3 months
- Tolerance/adaptation: A randomized, double‑blind 10‑day crossover (150 mg caffeine three times daily) showed impaired working‑memory performance during the caffeine phase vs placebo by Day 10, and withdrawal effects on discontinuation; fMRI indicated altered hippocampal activity. This suggests functional adaptation with daily high‑frequency intake [14].
- Moderator analyses: A meta‑analysis found acute attentional benefits are not moderated by habitual caffeine consumption status, implying that acute dosing remains effective across consumer types for attention RT/accuracy [1].
- Cycling/deload strategies: No randomized trials tested washout/cycling or “deload weeks” for preserving cognitive benefits. Pragmatically, sustaining efficacy over ≥3 months is best supported by:
  - Daily caps within official guidelines (≤400 mg/day; single doses ≤200 mg) [35–36].
  - Caffeine curfew of ≥6–8 h before habitual bedtime to protect sleep and next‑day functioning [35,38].
  - Use caffeine strategically (task‑ or shift‑linked boluses/maintenance) rather than continuous daily exposure throughout the day, to limit tolerance and protect sleep [1–5,14].
  - Prefer pure caffeine sources and consider SR earlier in the day to reduce peaks/jitter; avoid energy drinks with additional stimulants [16,18].
  - Note: These habits are grounded in RCT efficacy, PK, and safety/meta‑analytic data, but explicit RCTs on “cycling” or “deloads” are lacking [1–5,14–18].

## Moderators of effect
- Sleep status: Largest performance gains occur after sleep loss; dosing at the circadian trough is particularly effective [2–5].
- Genetics: In a 3 mg/kg crossover, CYP1A2 fast metabolizers showed larger PVT gains than slow metabolizers; ADORA2A variants were not associated with differential cognitive benefit in that trial [19].
- Habitual intake: Did not moderate acute attentional benefits in meta‑analysis, though daily multi‑dose exposure induces adaptation over ~10 days for working memory [1,14].
- Sex/age (20–65): Most samples are young adults; trials do not consistently report sex‑by‑treatment interactions. A female‑only sleep EEG study supports theanine’s mitigation of bedtime caffeine‑induced WASO at low doses [5].
- Task type/environment: Benefits are most consistent for vigilance/PVT, simple/choice RT, sustained attention; working‑memory benefits are smaller/less consistent in rested state [1–2,6–9,11,14].
- Source/formulation: Gum is appropriate when dosing close to task start; SR can smooth late‑day exposure; energy drinks can produce greater cardiovascular effects than matched caffeine [15–18].

## Practical, evidence‑based dosing playbook (healthy adults, 20–65; not medical advice)
- For a single daytime cognitive task (1–4 h):
  - 200–300 mg (≈2.5–4 mg/kg) of immediate‑release caffeine, 30–60 min pre‑task. Expect small–moderate RT/attention gains; accuracy gains plateau at higher doses [1,6–8,11,13].
  - If sensitive to jitter, consider 200 mg SR earlier in the morning for flatter coverage (slower onset), or keep to the lower end of the range [16].
- Executive attention/response inhibition (e.g., Stroop), visuomotor tasks:
  - ~3 mg/kg is a reliable choice for speeding responses without accuracy trade‑offs; avoid ≥6 mg/kg unless accepting more side effects [6–8,10,13].
- Extended wake/overnight or shift work:
  - Maintenance dosing beats a single bolus. Options: 200 mg at start of the night and 200 mg every ~2–4 h through the circadian trough, or 2 mg/kg repeated doses totaling ~4–6 mg/kg across the night; total nightly 400–800 mg used in RCTs. Do not expect full normalization; monitor cumulative dose and side effects [3–5].
- L‑theanine co‑ingestion:
  - For daytime attention under rest or sleep restriction: 160 mg caffeine + 200 mg theanine (~1.25:1) 50–60 min pre‑task has replicated benefits on attentional speed/accuracy and attention‑related EEG/fMRI signatures [22–24].
  - For high caffeine contexts (e.g., athletes using 6 mg/kg): consider matching theanine on a mg/kg basis (1:1), which improved Stroop RT/accuracy vs caffeine alone in elite athletes [26].
  - Near bedtime (if caffeine is taken, ideally avoid): 30 mg caffeine + 50 mg theanine mitigated WASO increase; do not extrapolate to larger evening doses [5].
- Long‑term habits to sustain efficacy and minimize sleep disruption/anxiety:
  - Keep daily intake ≤400 mg; single doses ≤200 mg [35–36].
  - Institute a ≥6–8 h caffeine curfew before bedtime; longer if sensitive or if dose is high [35,38].
  - Use caffeine purposefully (pre‑task or maintenance for shifts) rather than frequent daily grazing; avoid routine late‑day dosing [1–5,14].
  - Prefer pure caffeine (coffee, capsules, gum) over large energy drinks; avoid stacking with other stimulants [18,36].

## Limitations and research gaps
- Few adequately powered, preregistered crossover trials since 2017 directly compare caffeine alone vs caffeine+theanine on standardized cognitive batteries in non‑sport populations; more head‑to‑head work is needed [21–23,26].
- Anxiety/jitteriness outcomes and cardiovascular endpoints are inconsistently collected alongside cognition; high‑quality data comparing combo vs caffeine alone on these endpoints are limited post‑2017 [13,18,21–23,26].
- No randomized tests of caffeine cycling/deload schedules; evidence on tolerance mitigation is indirect (daily‑use adaptation and withdrawal) [14].

### Sources
[1] Acute caffeine and attention (rested adults) meta-analysis (2017–2025): https://pubmed.ncbi.nlm.nih.gov/40335666/?utm_source=openai  
[2] Caffeine after sleep loss meta-analysis: https://pubmed.ncbi.nlm.nih.gov/31837359/?utm_source=openai  
[3] Hansen 2019 (Psychopharmacology): 0/200/300 mg gum during 48 h TSD; PVT effects: https://pubmed.ncbi.nlm.nih.gov/30539266/  
[4] Killgore & Kamimori 2020 (Neurobiology of Sleep & Circadian Rhythms): 200 mg q2h overnight across TSD nights: https://pubmed.ncbi.nlm.nih.gov/33364521/  
[5] Khcharem 2022 (Chronobiology International): 2 mg/kg ×3 vs 6 mg/kg during TSD night: https://pubmed.ncbi.nlm.nih.gov/35791877/  
[6] Zhang 2020 (Frontiers in Psychology): 3/6/9 mg/kg Stroop RT and NIRS: https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2020.01393/full  
[7] Wang 2020 (IJERPH): 3 vs 6 vs 9 mg/kg; Stroop RT; side effects: https://pubmed.ncbi.nlm.nih.gov/32872249/?utm_source=openai  
[8] Sainz 2020 (Physiology & Behavior): 3 mg/kg in esports professionals; RT and accuracy: https://pubmed.ncbi.nlm.nih.gov/32593750/?utm_source=openai  
[9] 2024 esports dose–response (0/1/3 mg/kg) including PVT: https://pubmed.ncbi.nlm.nih.gov/39055173/?utm_source=openai  
[10] 2024 randomized crossover in elite shooters (3 mg/kg; Stroop and visual search): https://pubmed.ncbi.nlm.nih.gov/38267565/?utm_source=openai  
[11] Konishi 2018 (PLoS One): 200 mg; shifting attention and simulated driving: https://pubmed.ncbi.nlm.nih.gov/30379815/  
[12] Dynamic visual acuity with 4 mg/kg: https://pubmed.ncbi.nlm.nih.gov/34420061/?utm_source=openai  
[13] 2024 pre‑registered RCT (3 vs 6 mg/kg; RT improved only at 6 mg/kg; more nervousness): https://pubmed.ncbi.nlm.nih.gov/39231871/?utm_source=openai  
[14] Lin 2023 (Scientific Reports): 10‑day daily caffeine (150 mg ×3/day) vs placebo vs withdrawal; working memory and fMRI: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849460/?utm_source=openai  
[15] Chewing gum vs beverage PK (~50 mg): similar tmax; gum delivered ~18% less: https://pubmed.ncbi.nlm.nih.gov/29230348/  
[16] Thanawala 2024: sustained‑release vs immediate‑release 200 mg PK and subjective jitter/alertness: https://pubmed.ncbi.nlm.nih.gov/36602880/  
[17] 2025 mouth spray vs coffee vs energy drink PK and brief cognition: https://pubmed.ncbi.nlm.nih.gov/40000478/?utm_source=openai  
[18] Shah 2017 (JAHA): Energy drink (320 mg) vs matched caffeine; QTc and central BP: https://www.ahajournals.org/doi/full/10.1161/JAHA.116.004448?utm_source=openai  
[19] 2020 crossover on CYP1A2/ADORA2A moderators at 3 mg/kg: https://pubmed.ncbi.nlm.nih.gov/32356023/?utm_source=openai  
[20] Gum timing in cyclists (absorption/onset context): https://pubmed.ncbi.nlm.nih.gov/22476164/?utm_source=openai  
[21] 2024 meta‑analysis of theanine+caffeine RCTs (attention outcomes): https://pubmed.ncbi.nlm.nih.gov/40314930/?utm_source=openai  
[22] Kahathuduwa 2018 (Nutr Res): Rested men, 200 mg theanine + 160 mg caffeine; RT and fMRI: https://pubmed.ncbi.nlm.nih.gov/29420994/  
[23] Nawarathna 2025 (Br J Nutr): Sleep‑deprived adults; 200 mg theanine + 160 mg caffeine; RT, hit rate, P3b: https://pubmed.ncbi.nlm.nih.gov/40789769/  
[24] Br J Nutr full text (Cambridge Core) for [23]: https://www.cambridge.org/core/product/identifier/S0007114525104169/type/journal_article  
[25] Food & Function 2023: Bedtime 30 mg caffeine; theanine 50 mg suppresses WASO increase: https://pubs.rsc.org/en/content/articlelanding/2023/fo/d3fo01247f  
[26] Yilmaz 2023 (J Int Soc Sports Nutr): 6 mg/kg caffeine ± 6 mg/kg theanine; Stroop RT/accuracy: https://pubmed.ncbi.nlm.nih.gov/37815006/  
[27] Theanine monotherapy (100–400 mg) dose–response in rested adults: https://pubmed.ncbi.nlm.nih.gov/36263942/?utm_source=openai  
[28] Theanine monotherapy in sleep‑deprived adults (selective attention): https://pubmed.ncbi.nlm.nih.gov/39052627/?utm_source=openai  
[29] Dodd 2015 (Psychopharmacology; preregistered NCT00981955): low tea‑equivalent doses; NIRS and behavior: https://pubmed.ncbi.nlm.nih.gov/25761837/?utm_source=openai  
[30] Haskell 2008 (Biol Psychol): caffeine alone vs theanine alone vs combination; attention and working memory: https://pubmed.ncbi.nlm.nih.gov/18006208/?utm_source=openai  
[31] Giesbrecht/Rowson tea‑equivalent context (e.g., Appetite/Nutr Neurosci era): https://pubmed.ncbi.nlm.nih.gov/18681988/?utm_source=openai  
[32] Smith 2007 (“Time for tea”): BP/jitteriness modulation by tea constituents: https://pubmed.ncbi.nlm.nih.gov/17891480/?utm_source=openai  
[33] CDEK record for NCT00981955 preregistration: https://cdek.pharmacy.purdue.edu/trial/NCT00981955/?utm_source=openai  
[34] ClinicalTrials.gov NCT04056650 (n‑of‑1 platform; caffeine vs caffeine+theanine; terminated early): https://clinicaltrials.gov/study/NCT04056650  
[35] EFSA Scientific Opinion on caffeine safety (single‑dose and daily caps; sleep): https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2015.4102  
[36] FDA “Spilling the Beans” (400 mg/day context; typical beverage amounts): https://www.fda.gov/consumers/consumer-updates/spilling-beans-how-much-caffeine-too-much  
[37] Health Canada guidance on caffeine in foods (adult 400 mg/day cap; content ranges): https://www.canada.ca/en/health-canada/services/food-nutrition/food-safety/food-additives/caffeine-foods.html  
[38] Drake 2013 (J Clin Sleep Med): 400 mg caffeine 0/3/6 h pre‑bedtime disrupts sleep at all intervals: https://jcsm.aasm.org/doi/10.5664/jcsm.3170